Sabrina Maisel

Sabrina Maisel, Ph.D., has contributed to oncology research for over a decade, including developing complex 3D culture models of numerous cancer types. Prior to joining Stemson, Dr. Maisel worked in Pfizer's Oncology R&D division with an emphasis on introducing genetic perturbations in both mouse and human organoids for target nomination and validation. She has also worked in small biotech as an organoid specialist for SEngine Precision Medicine, using high-throughput screening to match cancer patients with on-the-market therapeutics to guide treatment plans. Dr. Maisel earned her Ph.D. in Cancer Biology from the University of Arizona with Prof. Joyce Schroeder, investigating the role of alternative EGFR trafficking in driving triple negative cancer progression. Her postdoctoral fellowship built on this research to evaluate the efficacy of hydrocarbon stapling of synthetic peptides targeting a range of EGFR-driven cancers. Additionally, she enjoys community outreach, guest lecturing at various academic institutions, and maintaining an "Ask a Scientist" column for K-12 students.